Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13

Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy rating on the shares. The firm adjusted estimates on the stock as part of a fiscal Q1 earnings preview for the commercial stage companies under its coverage in the biotechnology sector.

Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025?

In its audited consolidated financial results for the year ended December 31, 2025, Valneva SE (NASDAQ:VALN) reported total revenues of  €174.7 million, in line with guidance, including €157.9 million in product sales. The company also announced a strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing and a 21% reduction in operating cash burn.

Valneva SE (NASDAQ:VALN) also reiterated its fiscal year 2026 outlook and financial guidance, reporting that the first Phase 3 data readout for Lyme disease vaccine candidate (VLA15) is expected in the first half of 2026. Regulatory submissions are anticipated to follow as planned by Pfizer, subject to positive results.

Valneva SE (NASDAQ:VALN) is a specialty vaccine company involved in the development, manufacture, and commercialization of prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company currently offers three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ.

While we acknowledge the risk and potential of VALN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VALN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.